Abbott Laboratories ABT shares are trading lower Wednesday after the company reported financial results.
Abbott said second-quarter revenue increased 10.1% year-over-year to $11.3 billion, which beat the estimate of $10.29 billion, according to data from Benzinga Pro. Global COVID-19 testing-related sales reached 2.3 billion in the second quarter.
Abbott reported quarterly adjusted earnings of $1.43 per share, which beat the estimate of $1.12 per share.
"We achieved another quarter of strong growth and are raising our full-year EPS guidance," said Robert Ford, chairman and CEO of Abbott.
Abbott increased its full-year adjusted earnings guidance to "at least" $4.90 per share versus the estimate of $4.88 per share.
Related Link: Recap: Abbott Laboratories Q2 Earnings
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits and branded generic drugs.
ABT Price Action: Abbott has traded between $142.60 and $101.24 over a 52-week period.
The stock was down 3.31% at $106.29 at press time.
Photo: Grant is a Grant from Flickr.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.